Quince Therapeutics, Inc. (QNCX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Quince Therapeutics reported revenue of $0. Net income was -$84.0M, or -$336.00 per diluted share. Operating activities generated -$41.4M of cash, leaving -$41.8M of free cash flow. At fiscal year end, Quince Therapeutics held $93.5M in total assets against $129.2M in total liabilities, including $5.8M of cash and equivalents.
Open the full interactive Quince Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Quince Therapeutics Key Stats
| Share Price | $27.87 |
|---|---|
| Market Cap | $170.9M |
| 52-Week Range | $16.00 – $880.00 |
| Shares Outstanding | 6.1 million (basic, 2026 Q2) |
Quince Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$78.9M | -$90.3M | -$52.0M | -$34.6M | -$57.3M | -$58.1M |
| Pre-Tax Income | -$76.8M | -$89.9M | -$51.9M | -$31.6M | -$56.7M | -$80.8M |
| Income Tax | $0 | — | -$284,000 | $197,000 | $87,000 | $3.2M |
| Net Income | -$76.8M | -$89.9M | -$51.7M | -$31.4M | -$56.8M | -$84.0M |
| Diluted EPS | -$526.00 | -$606.00 | -$308.00 | -$168.00 | -$262.00 | -$336.00 |
Quince Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$13.4M | -$39.5M | $35.9M | -$75.5M |
| Diluted EPS | -$50.00 | -$0.79 | $57.60 | -$12.31 |
Quince Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | — | — | — | — | $5.8M |
| Current Assets | $137.9M | $111.7M | $93.7M | $77.4M | $44.0M | $22.9M |
| Total Assets | $189.5M | $133.2M | $103.9M | $167.9M | $114.5M | $93.5M |
| Current Liabilities | $17.0M | $14.2M | $3.1M | $9.6M | $7.3M | $43.2M |
| Total Long-Term Debt | — | — | — | $13.4M | $14.3M | $18.0M |
| Total Liabilities | $17.2M | $14.6M | $3.3M | $82.8M | $84.3M | $129.2M |
| Shareholders' Equity | $172.3M | $118.6M | $100.6M | $85.1M | $30.1M | -$35.7M |
Quince Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$50.8M | -$62.9M | -$44.0M | -$18.3M | -$31.9M | -$41.4M |
| Cash From Investing | -$52.4M | $59.0M | $18.0M | -$5.8M | $21.9M | $23.2M |
| Cash From Financing | $118.9M | $6.8M | $707,000 | $143,000 | -$4.8M | $17.9M |
| Free Cash Flow | -$50.9M | -$63.1M | -$44.2M | -$18.5M | -$32.2M | -$41.8M |
Figures from Quince Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Quince Therapeutics financials page for every line item.
Quince Therapeutics Company Profile
| Ticker | QNCX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | South San Francisco, California |
| Incorporated in | California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001662774 |
Frequently Asked Questions
What was Quince Therapeutics' revenue in fiscal 2025?
Quince Therapeutics (QNCX) reported revenue of $0 for fiscal 2025.
What is Quince Therapeutics' annual revenue history?
Quince Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Quince Therapeutics' net income in fiscal 2025?
Quince Therapeutics reported net income of -$84.0M for fiscal 2025.
What was Quince Therapeutics' earnings per share (EPS) in fiscal 2025?
Quince Therapeutics' diluted EPS was -$336.00 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Quince Therapeutics generate in fiscal 2025?
Quince Therapeutics generated -$41.8M of free cash flow in fiscal 2025.
What was Quince Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Quince Therapeutics reported revenue of $0.
How much debt does Quince Therapeutics have?
Quince Therapeutics reported $18.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Quince Therapeutics are outstanding?
Quince Therapeutics reported a weighted average of 6.1 million basic shares outstanding in 2026 Q2.
What is Quince Therapeutics' market cap?
Based on its latest closing price, Quince Therapeutics (QNCX) has a market capitalization of about $170.9M.
When does Quince Therapeutics' fiscal year end?
Quince Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Quince Therapeutics headquartered?
Quince Therapeutics lists its business address in South San Francisco, California in its SEC filings.
Quince Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →